Dynavax Technologies Corporation (0IDA.L)
| Previous close | 11.40 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,118 |
| Market cap | 2.379M |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | 0.15 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.
- PR Newswire
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023.
- PR Newswire
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, after the U.S. financial markets close.
